In vitro study of r-hirudin permeability through membranes of different haemodialysers

Nephrology Dialysis Transplantation

Volumn 14, Issue 12, 1999, Pages 2922-2926

  Bucha, Elke ^a,b   Kreml, Reiner ^a   Nowak, Goetz ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MAX PLANCK INSTITUTE   (Germany)

Author keywords

Haemodialysis; Membrane permeability; r hirudin

Indexed keywords

ALBUMIN; CELLULOSE; CELLULOSE ACETATE; DRUG CARRIER; ECARIN; LEPIRUDIN; POLYSULFONE;

ARTICLE; BLOOD; BLOOD CLOTTING TIME; CATTLE; CONTROLLED STUDY; DEVICE; DIALYSIS MEMBRANE; DRUG PENETRATION; HEMODIALYSIS; MEMBRANE PERMEABILITY; MODEL; PRIORITY JOURNAL;

EID: 0032713733     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.12.2922     Document Type: Article

References (19)

1. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23
2. Challapalli R, Lefkovits J, Topol EJ. Clinical trials of recombinant hirudin in acute coronary syndromes. Coron Artery Dis 1996; 7: 429-437
3. Kakkar VV, Delorenzo F. Therapeutic uses of recombinant hirudins. Cardiovasc Risk Factors 1996; 6: 148-151
4. Becker RC, Cannon ChP. Hirudin: its biology and clinical use. J Thrombosis Thrombolysis 1994; 1: 7-16
5. Schiele F, Lindgaerde F, Eriksson H et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs-a multicentre prospective dose-ranging randomized trial. Thromb Haemost 1997; 77: 834-838
6. Thieler H, Goeoeck Th, Nowak G. 1st Hirudin als Antikoagulans bei dialysepflichtigen Patienten geeignet? Nieren-und Hochdruckkranheiten 1991; 20: 453
7. Vanholder RC, Camez AA, Veys NM, Soria J, Mirshahi M, Soria C, Ringoir S. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 1994; 45: 1754-1759
8. Wyk van V, Badenhorst PN, Luus HG, Kotzé HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338-1343
9. Nowak G, Bucha E, Czenvinski R, Thieler H. Hirudin-a new anticoagulant in haemodialysis (HD). Pharmacol Res 1995; 31 [Suppl]: 335 [Abstract]
10. Nowak G, Bucha E, Brauns I, Czenvinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin induced thrombocytopenia (HIT II). Wien Klin Wochenschr 1997; 109: 354-358
11. Walenga JM, Koza MJ, Lewis BE, Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb/ Hemost 1996; 2 [Suppl. 1]: S21-S27
12. Boon DMS, van Vliet HHDM, Zietse R, Kappers-Klunne MC. The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemost 1996; 76: 480
13. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996; 28: 82-85
14. Markwardt F, Nowak G, Stürzebecher J, Vogel G. Clinico-pharmacological studies with recombinant hirudin. Thromb Res 1985; 52: 393-400
15. Nowak G, Bucha E, Goeoeck Th, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707-715
16. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997; 77: 650-655
17. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22: 197-202
18. Bucha E, Markwardt F, Nowak G. Hirudin in haemodialysis. Thromb Res 1990; 60: 445-455
19. Riess FC, Poetzsch B, Jaeger K, Bleese N, Schaper W, Mueller-Berghaus G. Elimination von rekombinantem Hirudin aus der Blutzirkulation mittels Hämofiltration. Hämostaseologie 1997; 17: 200-204